Insmed reported $727.62M in Debt for its fiscal quarter ending in March of 2026.





Debt Change Date
BioMarin Pharmaceutical USD 1.44B 833.74M Mar/2026
Cytokinetics USD 1.29B 4.48M Mar/2026
DBV Technologies USD 8.59M 295K Sep/2025
Gilead Sciences USD 24.94B 5M Dec/2025
Heron Therapeutics USD 149.65M 157K Sep/2024
Insmed USD 727.62M 275K Mar/2026
Novartis USD 32.02B 615M Sep/2025
Regeneron Pharmaceuticals USD 2.71B 300K Mar/2026
Sarepta Therapeutics USD 1.04B 210.44M Dec/2025
Ultragenyx Pharmaceutical USD 36M 2.17M Dec/2025
Vertex Pharmaceuticals USD 1.99B 44M Mar/2026